Presentation (CTI)

OBJECTIVES: To evaluate the effectiveness of HPV programs across European countries by assessing changes in HPV infection rates and associated cancer outcomes.
METHODS: We analyzed epidemiological data from 2018-2024 across 10 European countries, focusing on HPV vaccination coverage, incidence of HPV infections, and cervical cancer rates. Data sources included the European Centre for Disease Prevention and Control, national cancer registries and peer- reviewed publications. Countries were grouped based on vaccination coverage levels (high vs. low),and comparisons by gender and age group.
RESULTS: In countries with high vaccination coverage (The UK, Sweden and the Netherlands), there was a market decline in both HPV infections rates and cervical cancer incidence, especially among women aged 15- 29. These countries implemented early, school based or population-wide vaccination strategies. Conversely, in countries with low or inconsistent vaccination coverage (Bulgaria, Romania) HPV infections rates remain high. Although, progression to cancer is not always observed, persistent infections suggest ongoing transmission and elevated long-term risk. Countries with gender- neutral vaccination also reported early signs of reduced transmission among males.
CONCLUSIONS: HPV vaccination has led to measurable reductions in infections and cancer rates in countries with robust, early vaccination strategies. Disparities across Europe persist. In nations with low coverage, infection remains prevalent despite the absence of short- term cancer increases. These findings emphasize the need of expanded vaccination access, improved public health infrastructure, and targeted education to reduce HPV- related disease burden equitably across Europe.